Put companies on watchlist
Fielmann Group AG
ISIN: DE0005772206
WKN: 577220
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Fielmann Group AG · ISIN: DE0005772206 · EQS - Company News (35 News)
Country: Germany · Primary market: Germany · EQS NID: 2088171
04 March 2025 07:28AM

Fielmann Group preliminary financials for FY2024


EQS-News: Fielmann Group AG / Key word(s): Preliminary Results
Fielmann Group preliminary financials for FY2024

04.03.2025 / 07:28 CET/CEST
The issuer is solely responsible for the content of this announcement.


Fielmann Group preliminary financials for FY2024
Sales grow +15% to € 2.3 billion, profitability jumps +23%

  • FY2024 preliminary numbers in line with capital market guidance published in July 2024
  • Group adj. EBITDA grows by 23%, in Europe the margin is up +2.1 %pt. (to 22.8%)
  • Primary eyecare grows rapidly in Europe: already 130,000 Eye Health Check Ups

In 2024, the Fielmann Group generated consolidated sales of about €2.3 billion, a 15% increase compared to the previous year (€2.0 billion). This was due to strong organic growth (+7%) and the consolidation of our US acquisitions (+8%). The Fielmann Group also significantly improved its profitability: The adjusted EBITDA margin rose to circa 21.7% at Group level (+1.5 percentage points vs. last year), and to about 22.8% (+2.1 percentage points vs. last year) in Europe while Fielmann USA improved its adjusted EBITDA margin to 9.9%, all in line with our guidance.

Market share gains across major geographies
Despite macroeconomic headwinds and low consumer sentiment, Fielmann in FY2024 continued its strong organic sales growth in Central Europe: According to preliminary financials, Germany grew +7%, Switzerland went up +5% and our sales in Austria improved by +10% compared to the previous year. This development was driven by a significant increase in progressive lenses and an impressive performance of our hearing aids business. Our Spanish business grew at +10% versus the previous year. In our other European markets, we increased our sales by +5%. This includes double-digit growth in Poland and the Czech Republic as well as a decline in Italy attributable to a store network consolidation which significantly improved the country’s profitability.

Fielmann USA grew to about €200 million in 2024, primarily driven by the first full-year consolidation of SVS Vision as well as the consolidation of the first six months of our Shopko Optical business from July onwards. On a like-for-like basis, the sales of our US business increased by +11% compared to last year, outperforming the market.

Strong sales growth across major categories, huge demand for primary eyecare in Europe
According to FY2024 preliminary sales figures, the Fielmann Group benefitted from strong growth of 6% or more across every major category. In Europe, organic growth in contact lenses was flat, sunglasses without prescription grew +6%, prescription eyewear rose by 7% and hearing aids jumped by 10%. Our primary eyecare business has grown to sales of about €40 million in 2024. This development was primarily driven by our US acquisitions. In the United States, primary eyecare is a key component of our business. In Europe, Fielmann fulfils a long-held customer wish with its Eye Health Check Up: Since the inception more than 130,000 customers have opted for our innovative service in Germany, Switzerland and Austria. This medical offering grows rapidly as the number of Check Ups per store per day rises and the service is becoming available at ever more Fielmann stores across Europe.

Strong profitability increases in line with FY2024 guidance, dividend increases correspondingly
According to preliminary figures, the Fielmann Group increased its FY2024 adjusted EBITDA by about +23% to €491 million (previous year: €399 million). This development was driven by strong organic growth in Europe due to an improved sell-out mix and notable growth in our hearing aids business as well as stringent cost control. The Group’s adjusted EBITDA margin increased by about +1.5 percentage points to 21.7% (previous year: 20.2%). The same margin in Europe rose by circa +2.1 percentage points to 22.8% in 2024 (previous year: 20.7%). In the United States, the FY2024 adjusted EBITDA margin has improved to about 9.9%. The adjusted earnings before taxes (EBT) for the Fielmann Group as a whole jumped by circa 23% to about €237 million (previous year: €193 million).

Considering the successful development of the Group in 2024, the Management Board and Supervisory Board have decided to recommend an increased dividend of €1.15 per share (previous year: €1.00) to the Annual General Shareholder Meeting on July 10, 2025.

Outlook
Despite macroeconomic headwinds in many European markets, the Fielmann Group continues to thrive – thanks to loyal customers, its attractive value-for-money offering, its best-in-class service and stringent cost control. Our market share gains in 2024 make us optimistic that we continue to grow our market position this year. With our Vision 2025 growth strategy we successfully accelerated the growth pace of our family business. In light of our recent profitability improvements, the Fielmann Group is on track to deliver its 25% adjusted EBITDA margin goal in Europe as well as its 24% adjusted EBITDA margin goal at Group level. A more detailed guidance for FY2025 will be reviewed by our Supervisory Board in April and published subsequently in our Annual Report.

Hamburg, Germany – March 4, 2025

Fielmann Group AG
The Management Board

About Fielmann Group AG
The Fielmann Group is a German family business that serves 29 million customers with eyewear, contact lenses, hearing aids and primary eyecare services. It operates an omnichannel platform consisting of digital sales channels and more than 1,200 retail stores worldwide. Founded in 1972, the company is led by Marc Fielmann, representing the second generation of the Fielmann Family who still owns the majority of the company’s stock. By staying true to its customer-centric values, the Fielmann Group helps everyone hear and see the beauty in the world. Thanks to the dedication of its 24,000 people worldwide, the company is consistently reaching customer satisfaction and retention rates of more than 90% and has to-date fitted more than 200 million pairs of individual prescription glasses. 

Further information

Katrin Carstens
Director Communication & PR
press@fielmann.com
Phone +49 40 270 76 5907
Nils Scharwaechter
Investor Relations Manager
investorrelations@fielmann.com
Phone +49 40 270 76 511

 



04.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Fielmann Group AG
Weidestrasse 118 a
22083 Hamburg
Germany
Phone: +49 40 270 76-0
Fax: +49 40 270 76-390
Internet: www.fielmann-group.com
ISIN: DE0005772206
WKN: 577220
Indices: SDAX
Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Regulated Unofficial Market in Tradegate Exchange
EQS News ID: 2088171

 
End of News EQS News Service

2088171  04.03.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2088171&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Fielmann Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.